Substance P receptor mediated maintenance of chronic inflammation in EAE

Emily K. Reinke; Matthew J. Johnson; Changying Ling; Jozsef Karman; Jang Eun Lee; Joel V. Weinstock; Matyas Sandor; Zsuzsa Fabry

doi:10.1016/j.jneuroim.2006.07.010

Substance P receptor mediated maintenance of chronic inflammation in EAE

Emily K. Reinke, Matthew J. Johnson, Changying Ling, Jozsef Karman, Jang Eun Lee, Joel V. Weinstock, Matyas Sandor, Zsuzsa Fabry

Research output: Contribution to journal › Article › peer-review

30 Scopus citations

Abstract

Substance P (SP) is a modulatory, pro-inflammatory neuropeptide. We investigated the role of the SP receptor, neurokinin-1 (NK-1), in EAE. Our data show that in the chronic phase, mice lacking NK-1 have improved mobility and decreased numbers of LFA-1 high CD4+ T cells and MOG-specific, IFN-γ producing CD4+ T cells. SR140333, an NK-1 antagonist, administered alone during the chronic phase of EAE was not sufficient to ameliorate symptoms. These results indicate that SP, through NK-1, contributes to maintenance of CNS inflammation, and combining NK-1 antagonists with conventional anti-inflammatory treatments may enhance the success of treatments for diseases like multiple sclerosis.

Original language	English (US)
Pages (from-to)	117-125
Number of pages	9
Journal	Journal of Neuroimmunology
Volume	180
Issue number	1-2
DOIs	https://doi.org/10.1016/j.jneuroim.2006.07.010
State	Published - Nov 1 2006
Externally published	Yes

Keywords

EAE
MS
Neurokinin
Neuropeptide
SR140333
Substance P

Access

10.1016/j.jneuroim.2006.07.010

Fingerprint Dive into the research topics of 'Substance P receptor mediated maintenance of chronic inflammation in EAE'. Together they form a unique fingerprint.

Cite this

@article{771cd21baa9c4638a458f5d8c0110e8e,

title = "Substance P receptor mediated maintenance of chronic inflammation in EAE",

abstract = "Substance P (SP) is a modulatory, pro-inflammatory neuropeptide. We investigated the role of the SP receptor, neurokinin-1 (NK-1), in EAE. Our data show that in the chronic phase, mice lacking NK-1 have improved mobility and decreased numbers of LFA-1 high CD4+ T cells and MOG-specific, IFN-γ producing CD4+ T cells. SR140333, an NK-1 antagonist, administered alone during the chronic phase of EAE was not sufficient to ameliorate symptoms. These results indicate that SP, through NK-1, contributes to maintenance of CNS inflammation, and combining NK-1 antagonists with conventional anti-inflammatory treatments may enhance the success of treatments for diseases like multiple sclerosis.",

keywords = "EAE, MS, Neurokinin, Neuropeptide, SR140333, Substance P",

author = "Reinke, {Emily K.} and Johnson, {Matthew J.} and Changying Ling and Jozsef Karman and Lee, {Jang Eun} and Weinstock, {Joel V.} and Matyas Sandor and Zsuzsa Fabry",

year = "2006",

month = nov,

day = "1",

doi = "10.1016/j.jneuroim.2006.07.010",

language = "English (US)",

volume = "180",

pages = "117--125",

journal = "Journal of Neuroimmunology",

issn = "0165-5728",

publisher = "Elsevier",

number = "1-2",

}

TY - JOUR

T1 - Substance P receptor mediated maintenance of chronic inflammation in EAE

AU - Reinke, Emily K.

AU - Johnson, Matthew J.

AU - Ling, Changying

AU - Karman, Jozsef

AU - Lee, Jang Eun

AU - Weinstock, Joel V.

AU - Sandor, Matyas

AU - Fabry, Zsuzsa

PY - 2006/11/1

Y1 - 2006/11/1

N2 - Substance P (SP) is a modulatory, pro-inflammatory neuropeptide. We investigated the role of the SP receptor, neurokinin-1 (NK-1), in EAE. Our data show that in the chronic phase, mice lacking NK-1 have improved mobility and decreased numbers of LFA-1 high CD4+ T cells and MOG-specific, IFN-γ producing CD4+ T cells. SR140333, an NK-1 antagonist, administered alone during the chronic phase of EAE was not sufficient to ameliorate symptoms. These results indicate that SP, through NK-1, contributes to maintenance of CNS inflammation, and combining NK-1 antagonists with conventional anti-inflammatory treatments may enhance the success of treatments for diseases like multiple sclerosis.

AB - Substance P (SP) is a modulatory, pro-inflammatory neuropeptide. We investigated the role of the SP receptor, neurokinin-1 (NK-1), in EAE. Our data show that in the chronic phase, mice lacking NK-1 have improved mobility and decreased numbers of LFA-1 high CD4+ T cells and MOG-specific, IFN-γ producing CD4+ T cells. SR140333, an NK-1 antagonist, administered alone during the chronic phase of EAE was not sufficient to ameliorate symptoms. These results indicate that SP, through NK-1, contributes to maintenance of CNS inflammation, and combining NK-1 antagonists with conventional anti-inflammatory treatments may enhance the success of treatments for diseases like multiple sclerosis.

KW - EAE

KW - MS

KW - Neurokinin

KW - Neuropeptide

KW - SR140333

KW - Substance P

UR - http://www.scopus.com/inward/record.url?scp=33750610585&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750610585&partnerID=8YFLogxK

U2 - 10.1016/j.jneuroim.2006.07.010

DO - 10.1016/j.jneuroim.2006.07.010

M3 - Article

C2 - 16942803

AN - SCOPUS:33750610585

VL - 180

SP - 117

EP - 125

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

SN - 0165-5728

IS - 1-2

ER -